Paolo Cassano, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Depressive Disorder, Major | 26 | 2024 | 4745 | 2.980 |
Why?
|
| Infrared Rays | 6 | 2023 | 245 | 2.680 |
Why?
|
| Photochemotherapy | 2 | 2019 | 820 | 0.850 |
Why?
|
| Skull | 4 | 2019 | 815 | 0.850 |
Why?
|
| Brain | 12 | 2024 | 26947 | 0.700 |
Why?
|
| Neuralgia | 1 | 2024 | 600 | 0.580 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2018 | 189 | 0.560 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2018 | 123 | 0.540 |
Why?
|
| Lithium | 1 | 2019 | 596 | 0.540 |
Why?
|
| Phototherapy | 1 | 2019 | 368 | 0.540 |
Why?
|
| Antimanic Agents | 1 | 2019 | 520 | 0.510 |
Why?
|
| Antidepressive Agents, Second-Generation | 5 | 2006 | 489 | 0.490 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2024 | 1489 | 0.480 |
Why?
|
| Psychotropic Drugs | 1 | 2019 | 883 | 0.450 |
Why?
|
| Cerebrovascular Circulation | 2 | 2021 | 2731 | 0.440 |
Why?
|
| Anxiety Disorders | 4 | 2019 | 2714 | 0.440 |
Why?
|
| Dopamine Agonists | 3 | 2005 | 352 | 0.440 |
Why?
|
| Comorbidity | 7 | 2024 | 10495 | 0.390 |
Why?
|
| Antidepressive Agents | 8 | 2023 | 2889 | 0.390 |
Why?
|
| Double-Blind Method | 8 | 2024 | 12262 | 0.380 |
Why?
|
| Down Syndrome | 1 | 2019 | 892 | 0.380 |
Why?
|
| Neurodegenerative Diseases | 1 | 2020 | 1081 | 0.370 |
Why?
|
| Fluoxetine | 2 | 2005 | 733 | 0.360 |
Why?
|
| Brain Diseases | 1 | 2019 | 1541 | 0.350 |
Why?
|
| Hallucinations | 1 | 2013 | 366 | 0.350 |
Why?
|
| Psychotic Disorders | 3 | 2015 | 3193 | 0.350 |
Why?
|
| Glycine Hydroxymethyltransferase | 1 | 2009 | 32 | 0.340 |
Why?
|
| Body Weight | 1 | 2019 | 4603 | 0.320 |
Why?
|
| Drug Resistance | 2 | 2005 | 1593 | 0.310 |
Why?
|
| Periodicals as Topic | 1 | 2019 | 1462 | 0.310 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2009 | 275 | 0.300 |
Why?
|
| Electroencephalography | 2 | 2021 | 6187 | 0.300 |
Why?
|
| Sampling Studies | 2 | 2019 | 614 | 0.300 |
Why?
|
| Cognition | 3 | 2024 | 6953 | 0.280 |
Why?
|
| Cytokines | 2 | 2024 | 7338 | 0.270 |
Why?
|
| Depression | 8 | 2023 | 8057 | 0.270 |
Why?
|
| Alzheimer Disease | 3 | 2024 | 8544 | 0.260 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2024 | 881 | 0.240 |
Why?
|
| Treatment Outcome | 16 | 2023 | 64378 | 0.230 |
Why?
|
| Humans | 57 | 2024 | 758406 | 0.230 |
Why?
|
| Brain-Derived Neurotrophic Factor | 2 | 2024 | 597 | 0.230 |
Why?
|
| Pilot Projects | 4 | 2021 | 8553 | 0.220 |
Why?
|
| Depressive Disorder | 5 | 2018 | 3727 | 0.220 |
Why?
|
| Anxiety | 1 | 2018 | 4539 | 0.220 |
Why?
|
| Euphoria | 1 | 2022 | 65 | 0.210 |
Why?
|
| Female | 39 | 2024 | 390323 | 0.200 |
Why?
|
| Bipolar Disorder | 1 | 2019 | 5079 | 0.200 |
Why?
|
| Adult | 33 | 2024 | 219935 | 0.200 |
Why?
|
| Inflammation | 2 | 2024 | 10718 | 0.190 |
Why?
|
| Male | 37 | 2024 | 358747 | 0.190 |
Why?
|
| Ketamine | 2 | 2017 | 516 | 0.180 |
Why?
|
| Mental Disorders | 1 | 2020 | 6803 | 0.170 |
Why?
|
| Yoga | 1 | 2023 | 281 | 0.170 |
Why?
|
| Lasers, Semiconductor | 1 | 2019 | 41 | 0.170 |
Why?
|
| Hypertension | 1 | 2019 | 8499 | 0.170 |
Why?
|
| Thiazoles | 2 | 2004 | 1510 | 0.160 |
Why?
|
| Young Adult | 9 | 2024 | 58808 | 0.160 |
Why?
|
| Spectrum Analysis | 1 | 2021 | 451 | 0.160 |
Why?
|
| Middle Aged | 26 | 2024 | 219568 | 0.150 |
Why?
|
| Mood Disorders | 1 | 2024 | 1124 | 0.140 |
Why?
|
| Follow-Up Studies | 8 | 2019 | 39059 | 0.140 |
Why?
|
| Ubiquinone | 1 | 2018 | 182 | 0.140 |
Why?
|
| Lasers, Solid-State | 1 | 2019 | 175 | 0.140 |
Why?
|
| Severity of Illness Index | 6 | 2019 | 15785 | 0.140 |
Why?
|
| Single-Blind Method | 1 | 2021 | 1570 | 0.140 |
Why?
|
| Maze Learning | 1 | 2018 | 477 | 0.140 |
Why?
|
| Indoles | 1 | 2005 | 1828 | 0.140 |
Why?
|
| Nose | 1 | 2020 | 519 | 0.130 |
Why?
|
| Stress, Psychological | 2 | 2024 | 4455 | 0.130 |
Why?
|
| Blood Pressure Determination | 1 | 2019 | 634 | 0.130 |
Why?
|
| Prefrontal Cortex | 3 | 2022 | 2209 | 0.120 |
Why?
|
| Hospitals, General | 1 | 2019 | 795 | 0.120 |
Why?
|
| Ascorbic Acid | 1 | 1998 | 655 | 0.120 |
Why?
|
| Cultural Competency | 1 | 2018 | 297 | 0.120 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 4 | 2012 | 1988 | 0.120 |
Why?
|
| Chi-Square Distribution | 2 | 2019 | 3425 | 0.120 |
Why?
|
| Oxidative Stress | 2 | 2023 | 3099 | 0.120 |
Why?
|
| Psychotherapy | 1 | 2023 | 1640 | 0.110 |
Why?
|
| Statistics, Nonparametric | 1 | 2019 | 2850 | 0.110 |
Why?
|
| Universities | 1 | 2018 | 993 | 0.110 |
Why?
|
| Catechol O-Methyltransferase | 2 | 2005 | 251 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2024 | 4342 | 0.100 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2022 | 1469 | 0.100 |
Why?
|
| Body Constitution | 1 | 1992 | 273 | 0.100 |
Why?
|
| Reference Values | 1 | 2019 | 4919 | 0.100 |
Why?
|
| Telomere | 1 | 2018 | 931 | 0.100 |
Why?
|
| Aged | 16 | 2024 | 168218 | 0.100 |
Why?
|
| History, 20th Century | 1 | 2019 | 2772 | 0.100 |
Why?
|
| Adolescent | 10 | 2019 | 87892 | 0.090 |
Why?
|
| Acculturation | 1 | 2012 | 178 | 0.090 |
Why?
|
| Cyclohexanols | 3 | 2006 | 126 | 0.090 |
Why?
|
| Forecasting | 1 | 2019 | 2923 | 0.090 |
Why?
|
| Antipsychotic Agents | 2 | 2015 | 3060 | 0.090 |
Why?
|
| Neuropsychological Tests | 3 | 2021 | 7021 | 0.090 |
Why?
|
| Cohort Studies | 7 | 2019 | 41256 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2009 | 15773 | 0.090 |
Why?
|
| Sex Factors | 2 | 2019 | 10504 | 0.090 |
Why?
|
| Testosterone | 1 | 2020 | 2471 | 0.080 |
Why?
|
| Public Health | 1 | 2002 | 2658 | 0.080 |
Why?
|
| Hippocampus | 2 | 2018 | 3736 | 0.080 |
Why?
|
| Citalopram | 3 | 2006 | 402 | 0.080 |
Why?
|
| Language | 1 | 2018 | 1532 | 0.080 |
Why?
|
| Students | 1 | 2018 | 1734 | 0.080 |
Why?
|
| Drug Therapy, Combination | 3 | 2020 | 6293 | 0.080 |
Why?
|
| Sex Characteristics | 1 | 2018 | 2621 | 0.080 |
Why?
|
| Rural Population | 1 | 1998 | 2254 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 17768 | 0.070 |
Why?
|
| Cognition Disorders | 3 | 2007 | 3975 | 0.070 |
Why?
|
| Age Factors | 2 | 2019 | 18358 | 0.070 |
Why?
|
| Emotions | 1 | 2018 | 2734 | 0.070 |
Why?
|
| Boston | 1 | 2019 | 9304 | 0.070 |
Why?
|
| Drug Administration Schedule | 4 | 2016 | 4839 | 0.070 |
Why?
|
| Suicidal Ideation | 1 | 2016 | 1430 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2015 | 22029 | 0.070 |
Why?
|
| Primary Health Care | 1 | 2002 | 4652 | 0.060 |
Why?
|
| Vasomotor System | 1 | 2006 | 207 | 0.060 |
Why?
|
| Benzothiazoles | 2 | 2004 | 246 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 3 | 2019 | 6209 | 0.060 |
Why?
|
| Mitochondria | 1 | 2018 | 3584 | 0.060 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2016 | 6013 | 0.060 |
Why?
|
| Motor Skills Disorders | 1 | 2005 | 89 | 0.060 |
Why?
|
| Polymorphism, Genetic | 2 | 2005 | 4284 | 0.060 |
Why?
|
| Anger | 1 | 2007 | 401 | 0.060 |
Why?
|
| Quality Improvement | 1 | 2019 | 3806 | 0.060 |
Why?
|
| Antidepressive Agents, Tricyclic | 2 | 2005 | 431 | 0.060 |
Why?
|
| Memory Disorders | 2 | 2018 | 1197 | 0.060 |
Why?
|
| Prospective Studies | 6 | 2019 | 54137 | 0.060 |
Why?
|
| Attitude to Health | 1 | 2013 | 2026 | 0.060 |
Why?
|
| Premenstrual Syndrome | 1 | 2004 | 107 | 0.060 |
Why?
|
| Valine | 1 | 2005 | 408 | 0.060 |
Why?
|
| Moclobemide | 1 | 2003 | 4 | 0.050 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2021 | 4560 | 0.050 |
Why?
|
| Schizophrenia | 3 | 2007 | 6910 | 0.050 |
Why?
|
| Methionine | 1 | 2005 | 569 | 0.050 |
Why?
|
| Gene Frequency | 1 | 2009 | 3612 | 0.050 |
Why?
|
| Paroxetine | 1 | 2003 | 182 | 0.050 |
Why?
|
| Time | 1 | 2004 | 543 | 0.050 |
Why?
|
| Time Factors | 2 | 2019 | 39872 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2009 | 21017 | 0.050 |
Why?
|
| Infusions, Intravenous | 2 | 2017 | 2210 | 0.050 |
Why?
|
| Adipose Tissue | 2 | 1993 | 3299 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 10146 | 0.050 |
Why?
|
| Body Temperature | 1 | 2024 | 777 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2016 | 10748 | 0.050 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2004 | 357 | 0.040 |
Why?
|
| Aging | 2 | 2018 | 8650 | 0.040 |
Why?
|
| Lung | 1 | 1998 | 9985 | 0.040 |
Why?
|
| Nurses | 1 | 2009 | 2467 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2009 | 9650 | 0.040 |
Why?
|
| Losartan | 1 | 2021 | 265 | 0.040 |
Why?
|
| Genotype | 3 | 2009 | 12945 | 0.040 |
Why?
|
| Postmenopause | 2 | 2006 | 2509 | 0.040 |
Why?
|
| Substance-Related Disorders | 2 | 2006 | 4402 | 0.040 |
Why?
|
| Gyrus Cinguli | 2 | 2020 | 1115 | 0.040 |
Why?
|
| Prognosis | 1 | 2019 | 29557 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2012 | 12951 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2019 | 23884 | 0.040 |
Why?
|
| Pregnancy | 1 | 2019 | 29742 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2024 | 36284 | 0.040 |
Why?
|
| Animals | 5 | 2024 | 167768 | 0.040 |
Why?
|
| Rural Health | 1 | 1998 | 296 | 0.030 |
Why?
|
| Neuroimmunomodulation | 1 | 2018 | 177 | 0.030 |
Why?
|
| Fatigue | 1 | 2004 | 1542 | 0.030 |
Why?
|
| Organ Culture Techniques | 1 | 2018 | 795 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2004 | 6354 | 0.030 |
Why?
|
| Prevalence | 1 | 2012 | 15651 | 0.030 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2021 | 1016 | 0.030 |
Why?
|
| Sertraline | 2 | 2006 | 208 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2024 | 3759 | 0.030 |
Why?
|
| Alcoholism | 1 | 2005 | 1962 | 0.030 |
Why?
|
| Risk Factors | 4 | 2009 | 73809 | 0.030 |
Why?
|
| Bupropion | 2 | 2006 | 304 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 1998 | 1680 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2002 | 2414 | 0.030 |
Why?
|
| Rabbits | 1 | 2019 | 4772 | 0.030 |
Why?
|
| Acute Disease | 1 | 2004 | 7225 | 0.030 |
Why?
|
| Models, Animal | 1 | 2019 | 2112 | 0.030 |
Why?
|
| United States | 3 | 2018 | 72136 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2017 | 1745 | 0.030 |
Why?
|
| Personality Inventory | 2 | 2006 | 1018 | 0.030 |
Why?
|
| Quality of Life | 2 | 2021 | 13285 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2005 | 2457 | 0.030 |
Why?
|
| China | 1 | 1998 | 2333 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 2020 | 1802 | 0.030 |
Why?
|
| Hip | 1 | 1992 | 251 | 0.020 |
Why?
|
| Obesity | 2 | 1993 | 12870 | 0.020 |
Why?
|
| Child | 1 | 2019 | 79818 | 0.020 |
Why?
|
| Antioxidants | 1 | 2018 | 1662 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2019 | 80168 | 0.020 |
Why?
|
| Behavior, Animal | 1 | 2018 | 1866 | 0.020 |
Why?
|
| Sleep | 1 | 2006 | 4744 | 0.020 |
Why?
|
| Remission Induction | 1 | 2016 | 2388 | 0.020 |
Why?
|
| Leukocytes | 1 | 2018 | 2025 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2002 | 2782 | 0.020 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2024 | 3701 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 1992 | 12075 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2019 | 8143 | 0.020 |
Why?
|
| Linear Models | 1 | 1998 | 5862 | 0.020 |
Why?
|
| Mice | 3 | 2019 | 81101 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2002 | 9267 | 0.020 |
Why?
|
| Abdomen | 1 | 1992 | 1129 | 0.020 |
Why?
|
| Norethindrone | 1 | 2006 | 56 | 0.020 |
Why?
|
| Psychometrics | 1 | 2016 | 3052 | 0.020 |
Why?
|
| Ethinyl Estradiol | 1 | 2006 | 114 | 0.020 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2006 | 303 | 0.020 |
Why?
|
| Dietary Fats | 1 | 1993 | 1991 | 0.020 |
Why?
|
| Adrenergic alpha-2 Receptor Antagonists | 1 | 2005 | 18 | 0.020 |
Why?
|
| Fatty Acids | 1 | 1993 | 1803 | 0.020 |
Why?
|
| Neurotransmitter Uptake Inhibitors | 1 | 2005 | 36 | 0.020 |
Why?
|
| Perimenopause | 1 | 2006 | 141 | 0.020 |
Why?
|
| Body Mass Index | 2 | 1993 | 12876 | 0.020 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2005 | 155 | 0.020 |
Why?
|
| Retreatment | 1 | 2006 | 596 | 0.010 |
Why?
|
| Buspirone | 1 | 2005 | 81 | 0.010 |
Why?
|
| Serotonin Antagonists | 1 | 2005 | 144 | 0.010 |
Why?
|
| Cerebral Ventricles | 1 | 2007 | 542 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 14641 | 0.010 |
Why?
|
| Luteal Phase | 1 | 2004 | 138 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2002 | 5816 | 0.010 |
Why?
|
| Body Composition | 1 | 1993 | 2416 | 0.010 |
Why?
|
| Hot Flashes | 1 | 2006 | 328 | 0.010 |
Why?
|
| Factor Analysis, Statistical | 1 | 2006 | 999 | 0.010 |
Why?
|
| Rats | 1 | 2019 | 23679 | 0.010 |
Why?
|
| Personality Assessment | 1 | 2005 | 650 | 0.010 |
Why?
|
| Apoptosis | 1 | 2018 | 9468 | 0.010 |
Why?
|
| Combined Modality Therapy | 2 | 2006 | 8530 | 0.010 |
Why?
|
| Norepinephrine | 1 | 2005 | 897 | 0.010 |
Why?
|
| Analysis of Variance | 2 | 2005 | 6234 | 0.010 |
Why?
|
| Drug Resistance, Multiple | 1 | 2002 | 253 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 22003 | 0.010 |
Why?
|
| Diet | 1 | 1998 | 8005 | 0.010 |
Why?
|
| Cerebrovascular Disorders | 1 | 2007 | 1475 | 0.010 |
Why?
|
| Temporal Lobe | 1 | 2007 | 1688 | 0.010 |
Why?
|
| Estrogens | 1 | 2006 | 1520 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2005 | 2925 | 0.010 |
Why?
|
| Infant | 1 | 2021 | 36055 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 2005 | 2381 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 18119 | 0.010 |
Why?
|
| Insulin | 1 | 1993 | 6578 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1992 | 6346 | 0.010 |
Why?
|
| Schizophrenic Psychology | 1 | 2005 | 1646 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 1992 | 12440 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 4567 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 25956 | 0.010 |
Why?
|
| Electroconvulsive Therapy | 1 | 2002 | 500 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2005 | 4106 | 0.010 |
Why?
|
| Suicide, Attempted | 1 | 2005 | 1383 | 0.010 |
Why?
|
| Aged, 80 and over | 3 | 2003 | 58683 | 0.010 |
Why?
|
| Suicide | 1 | 2006 | 1599 | 0.010 |
Why?
|
| Incidence | 1 | 1992 | 21272 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2005 | 2768 | 0.010 |
Why?
|
| Alleles | 1 | 2005 | 6895 | 0.010 |
Why?
|
| Risk | 1 | 2005 | 9599 | 0.010 |
Why?
|
| Logistic Models | 1 | 2007 | 13276 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2005 | 4406 | 0.010 |
Why?
|
| Physical Exertion | 1 | 1993 | 662 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 12759 | 0.010 |
Why?
|
| Anthropometry | 1 | 1993 | 1347 | 0.000 |
Why?
|
| Fasting | 1 | 1993 | 1599 | 0.000 |
Why?
|
| Smoking | 1 | 1993 | 9051 | 0.000 |
Why?
|